The growing number of individuals adhering to a gluten-free diet (GFD) without exclusion of celiac disease complicates its detection. HLA-DQ-gluten tetramers can be used to detect gluten-specific T cells in blood of patients with celiac disease, even if they are on a GFD. We investigated whether an HLA-DQ-gluten tetramer-based assay accurately identifies patients with celiac disease.
Methods:
We produced HLA-DQ-gluten tetramers and added them to peripheral blood mononuclear cells isolated from 143 HLA-DQ2.5+ subjects (62 subjects with celiac disease on a GFD, 19 subjects without celiac disease on a GFD [due to self-reported glutensensitivity], 10 subjects with celiac disease on a gluten-containing diet, and 52 presumed healthy individuals [controls] ). T cells that bound HLA-DQ-gluten tetramers were quantified by flow cytometry. Laboratory tests and flow cytometry gating analyses were performed by researchers blinded to sample type, except for samples from subjects with celiac disease on a gluten-containing diet. Test precision analyses were performed using samples from 10 subjects.
Results: For the HLA-DQ-gluten tetramer-based assay, we combined flow-cytometry variables in a multiple regression model that identified individuals with celiac disease on a GFD with an area under the receiver operating characteristic curve (AUROC) value of 0.96 (95% CI, 0.89-1.00) vs subjects without celiac disease on a GFD. The assay detected individuals with celiac disease on a gluten-containing diet vs controls with an AUROC value of 0.95 (95% CI, 0.90-1.00). Optimized cut-off values identified subjects with celiac disease on a GFD with 97% sensitivity (95% CI, 0.92-1.00) and 95% specificity (95% CI, 0.84-1.00),
Introduction
Celiac disease is a gluten-induced enteropathy treated with a life-long gluten-free diet (GFD). 1, 2 Around 90% of disease cases are HLA-DQ2.5 + , the remaining are either HLA-DQ8 + or HLA-DQ2.2 + .
3 CD4 + T cells recognizing deamidated gluten peptides in the context of these HLA-DQ molecules are a hallmark of the disease. 4 Celiac disease patients are usually identified by detection of elevated anti-transglutaminase 2 (anti-TG2) IgA and/or antideamidated gliadin peptide (anti-DGP) IgG antibodies in serum. In adults and about half of children, 5 the diagnosis is confirmed by demonstrating typical histological changes in duodenal biopsies. 6 Partly owing to a pronounced increase in the consumption of gluten-free foodstuffs in the general population, 7 many individuals presenting to the clinician are on a self-instituted GFD without prior diagnostic work-up for celiac disease. Much as a diagnostic work-up is recommended in this situation, 1, 2 it poses a substantial challenge for clinicians because initiation of a GFD decreases the sensitivity of histology-and antibody-based tests for celiac disease. 8, 9 In such cases, a gluten challenge with several weeks' duration followed by gastroduodenoscopy is suggested by the guidelines. 1, 2 A thoroughly conducted 6-week gluten challenge study of subjects with celiac disease treated with a GFD eating 3 g and 6 g gluten daily, gave correct diagnostic histology in 71% and 73%, respectively. 10 Increasing the duration of challenge to 12 weeks (three to five grams gluten daily) did not further increase the sensitivity. 11 Apart from the clinical challenges related to the low sensitivity of the gluten challenge protocol, some patients may not adhere to the protocol if having experienced gluten-related symptoms in the past. Thus, improved diagnostic tests for this patient group are much needed.
Over the last decade, we and others have characterized the diagnostic potential of glutenspecific T cells detected in blood after a short gluten challenge. [12] [13] [14] [15] [16] Moreover, by using HLA-DQ-gluten tetramers, we recently demonstrated that gluten-specific T cells are detectable in
blood of both untreated and treated celiac disease patients with a higher frequency than in non-celiac subjects, even in the absence of a gluten challenge. 17 In the present study we investigated the sensitivity and specificity of a modified version of this protocol for detection of celiac disease, in gluten-free and gluten consuming subjects separately. We evaluated this approach in the work-up of celiac disease as an alternative to gluten challenge in gluten-free subjects. Moreover, we explored its potential as a supplement to duodenal biopsy and serology in the work-up of subjects on a normal diet.
Materials and Methods

Trial design, inclusion and recruitment:
We included HLA-DQ2.5 + -adults in two groups with gluten-free subjects; 62 subjects with celiac disease treated with a GFD (TCD) and 19 subjects without celiac disease on a GFD due to self-reported gluten sensitivity (GS), and two groups with gluten consuming subjects;
10 untreated subjects with celiac disease on a gluten-containing diet (UCD)-subjects and 52
presumed healthy individuals on a gluten-containing diet (controls) (Supplementary figure 1).
Subjects were included in the TCD-group only if the celiac disease diagnosis was based on a duodenal biopsy and if they had been compliant with a GFD since (minimum requirement Biagi score ≥ 1; transgression of GFD limited to "just a taste" in rare events). 18 Similarly, GSsubjects were included only if celiac disease was excluded by duodenal histology while on a gluten-containing diet for at least three weeks and if they reported adequate compliance (Biagi score ≥ 1). We did not confirm self-reported gluten sensitivity by food challenge.
Controls denied any prior history of celiac disease and had been on a normal glutencontaining diet for at least 6 months. Exclusion criteria were immune suppressive treatment for the last 3 months, pregnancy, hepatitis B or C and a positive HIV status. In addition, we examined analytical and weekly variation of the HLA-DQ-gluten tetramer test.
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For this purpose, we included five TCD-subjects and five controls selected from the primary study cohort to represent different degrees of test response. Analytical variation was determined by comparing two halves of a blood sample divided prior to processing and biological variation by comparing two samples drawn one week apart from the same subject on an unaltered diet.
Sampling, blinding protocol and data collection:
We drew 54 mL citrated blood for the HLA-DQ-gluten tetramer test. Subjects met for blood sampling after randomization, the samples were de-identified (except for UCD-group) and processed the following day for flow cytometry. Flow-cytometric analysis, including the gating of cell populations, was done blinded for subject identity. Additional serum for anti-TG2 IgA 
HLA-DQ-gluten tetramers and flow cytometry analysis:
The HLA-DQ-gluten tetramers were produced as previously described. 20 Recombinant HLA- 
HLA-DQ-gluten tetramer test variables
We used flow-cytometric raw-data to calculate pre-defined parameters (frequency of glutenspecific T cells and variables 1 -3) by dividing the cell-population in question with a suitable M A N U S C R I P T
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reference cell-population in the same sample to correct for sample-and subject-dependent background variability and thereby to optimize normalization of variables (Table 1) .
Data transformations and multiple regression analysis
The variables were Box-Cox power transformed [B-C;λ] to correct for skewness. 21, 22 A common optimal lambda (λ) was established for GS and TCD groups; as well as for control and UCD groups. Stepwise multivariate linear regression analyses on transformed variables were done for the comparisons GS vs TCD and control vs UCD to find the optimal models. 
Cell-culture and proliferation assay
T-cell lines were generated from bulk-sorted HLA-DQ-gluten-tetramer + β7 + T EM by antigen free stimulation as previously described. 23 Antigen-dependent T-cell proliferation assay was performed using a well-established protocol by using HLA-DQ2. Data points with values below the lower detection limit were assigned half its value. The significance level was P < .05.
Ethical aspects
The study was approved by the regional ethical committee of South-East Norway (REK accession numbers 2010/2720 and 2011/2472) and registered at www.clinicaltrials.gov (NCT02442219). Written informed consent was obtained from all participants. All authors had access to the study data and reviewed and approved the final manuscript.
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Results
Participant characteristics
Both non-celiac groups (GS and control) were similar regarding age, body mass index, first degree relatives with celiac disease, daily smoking, other auto-immune disease, gastrointestinal symptoms and serum C-reactive protein level (Supplementary Table 1 ). The gluten-free TCD and GS groups were also similar in all these aspects in addition to adherence to GFD, but differed in duration of GFD (P = .034). The GS-group of 19 subjects was relatively small due to the strict inclusion-criteria requiring previous exclusion of celiac disease by duodenal histology while these subjects were still consuming gluten. Partly due to issues of recruitment, we limited the size of the UCD-group to 10 subjects, also because we expected larger differences in test response between celiac and non-celiac subjects in the groups with gluten consuming subjects than in the groups with gluten-free subjects.
Antibody-based tests were not sensitive for detecting TCD subjects
Of the 10 UCD-subjects, nine were anti-TG2 IgA-positive and eight were anti-DGP IgGpositive, significantly different from the antibody positivity in TCD and control groups (P Table 1) . One of 62 TCD-subjects was positive for anti-TG2 IgA only, four subjects were positive for anti-DGP IgG only, and one had elevated levels for both. Notably, four of 52 controls were seropositive for anti-DGP IgG and only these four subjects had measurable anti-TG2 IgA levels (≥ 1 unit/mL) amongst controls. All GS-subjects had undetectable anti-TG2 IgA levels, and all but one had undetectable anti-DGP IgG levels. No subjects had IgA deficiency.
< .001 for UCD vs TCD and UCD vs control for both antibodies) (Figure 2 & Supplementary
Flow-cytometric variables were significantly different in non-celiac and celiac disease
We assessed the ability of four variables based on flow-cytometric cell surface markers (Table 1) 
Optimal multiple regression models accurately differentiate non-celiac from celiac disease subjects, regardless of gluten consumption
For more accurate classification of subjects, we applied multiple regression analysis to construct two models based on variables 1 -3 ( Figure 4A & 4C) . We developed one model for the comparison TCD vs GS using all three variables as significant contributors, and the second model for UCD vs control with variables 1 -2 as significant contributors ( Table 2 ).
The parameter for frequency of gluten-specific T cells was strongly correlated to variable 1 for both comparisons (Pearson correlation r = 0.84 for GS vs TCD and r = 0.76 for control vs UCD after data transformation). This parameter was therefore omitted from the regression analysis for the benefit of variable 1, a variable that did not require additional counting and staining of a pre-tetramer-enriched sample.
ROC analysis defined the optimal cut-offs, giving an AUROC value of 0.96 (95% CI, 0.89- Figure 4C ), were found to be seropositive for celiac disease specific antibodies. One subject in the GS-group was index test positive. Although this GS participant documented a previously negative duodenal biopsy at the time of inclusion, when confronted with a positive index test result, she recalled that the biopsy was done after only two weeks of gluten challenge and a strict GFD for several months prior to that. We rechecked the biopsy and verified normal histology. Two subjects in the TCD-group were index test negative. One of them, diagnosed as a child in the early 1970's, participated also in a twoweek gluten challenge study and remained both histology and antibody negative. 25 
In controls with high frequency of HLA-DQ-gluten tetramer + cells, these cells were specific to gluten upon stimulation in vitro
Four of five index test positive controls, who were found to be seropositive for either anti-TG2
IgA or anti-DGP IgG, accepted invitation for diagnostic work-up of celiac disease in addition to two index-test negative and seronegative controls with a frequency of gluten-specific T cells on same level as UCD-subjects. All six control subjects underwent duodenal biopsies and celiac disease specific serology, 6 -12 months after the index test. Two index test positive controls had villous blunting on histological evaluation, and thus diagnosed with celiac disease (Supplementary Table 2 ). Among the remaining four individuals, the two index test positive subjects had some, but not sufficient histological changes to qualify for celiac disease diagnosis, and the two index test negative subjects had completely normal duodenal histology (Supplementary Table 2 ). In these four non-celiac controls, flow cytometry of PBMC Figure 2B) .
CD38-expression on gluten-specific T cells is as accurate as antibody-based tests to differentiate TCD from UCD
Motivated by previous results on CD38 as a marker that was upregulated on gluten-specific T cells after gluten challenge, 26 we investigated whether CD38-expression on HLA-DQgluten-tetramer + β7 + T EM was associated with the treatment-status of the celiac disease patients. The frequency of CD38 + gluten-specific T-cells was low in the non-celiac groups except for six controls with similar levels as the UCD-subjects, where the four seropositive controls displayed the topmost frequency (Supplementary Figure 3A) . We explored the celiac disease groups in greater detail by using the flow-cytometric variable CD38 RR , an estimate of CD38-expression normalized for background subject variability (Table 1) , and found the groups (TCD vs UCD) to be significantly different (P < .001) (Supplementary Figure 3B) . 
Analytical variation of the HLA-DQ-gluten tetramer test equals the weekly biological variation
The test of precision performed on samples from five TCD subjects and five controls that were divided into two halves before processing (analytical variation), showed a variation M A N U S C R I P T
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approximately equal to that of samples taken with one week interval (Supplementary Figure   4 and Supplementary Table 3) . CD is highly associated with certain HLA-allotypes, 3 and HLA-typing is utilized in clinical work-up of celiac disease. 1, 2 Although the absence of these disease-associated HLA allotypes may exclude celiac disease, the positive predictive value of the HLA-DQ2/8-typing remains low. 3 Determining the presence of gluten-reactive T cells in patients who carry celiac disease associated HLA-DQ allotypes may assist in further differentiation of disease status.
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The CD4 + T-cell reactivity in relation to celiac disease has been assessed by either HLA-DQgluten tetramer analysis or by T-cell cytokine release assays (ELISPOT / ELISA). 13, 15-17, 25, 27-29 The HLA-DQ-gluten tetramer approach uses fluorescent complexes of gluten peptides tethered to disease-specific HLA molecules for direct detection of gluten-specific cells in PBMC by flow cytometry. 20 In the ELISPOT test, PBMC are incubated with gluten-epitopes overnight, followed by an interferon-γ ELISPOT assay. 27 In the ELISA test, measurement of interferon-γ or interferon-γ-inducible protein 10 is done in whole blood after an overnight incubation with gluten-peptides. 16 With both ELISPOT and ELISA, the T-cell reactivity in PBMC is detectable only when combined with a 3-day oral gluten challenge and bloodsampling on day 6, 12, 16, 28, 29 when there is a surge of gluten-reactive T-cells in the blood. 27 Initially, the HLA-DQ-gluten tetramer approach also was used to detect a T-cell response to gluten in PBMC on day 6 after a 3-day oral gluten challenge. 13, 15 In a later study, the M A N U S C R I P T
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18 sensitivity of the assay was increased by magnetic bead enrichment for tetramer-binding T cells, 30 as positive response was detected in 11 of 13 HLA-DQ2.5 + TCD-subjects without the need of a gluten challenge. 17 In the current study, we further improved the protocol for the tetramer-based approach by pooling together five HLA-DQ-gluten tetramers, implementing gut-homing staining to all samples, reducing the required blood volume for the assay to an acceptable level and applying protocol automation for magnetic bead enrichment. Moreover, we identified and integrated new flow-cytometric variables to generate models that demonstrated a high degree of accuracy for correct prediction of celiac disease in a larger number of gluten consuming and gluten-free subjects, without applying gluten challenge.
The reference standard in the gluten-free groups of this study was exclusion of celiac disease by duodenal biopsy while the subjects were still consuming gluten. However, one index test positive GS-subject had inadequate prior exclusion of celiac disease, and one index test negative TCD-subject, diagnosed with celiac disease in the early 1970's, did not respond with duodenal changes after a two-week gluten challenge in another related study. 25 Both subjects may thus have contributed to a lower than actual estimate of sensitivity and specificity. By comparison, the highest reported estimates of diagnostic sensitivity of 2 -12-week gluten challenge followed by duodenal biopsy are approximately 70%. 10, 11, 31 This sensitivity may also be much lower, depending on the dose and duration of gluten challenge. 25 Thus, introducing the HLA-DQ-gluten tetramer blood test in this clinical setting could clearly benefit patients and clinicians by offering a faster, more sensitive and symptomfree test, as gluten challenge is known to induce unacceptable symptoms in some patients.
The new test may thus potentially replace gluten challenge followed by duodenal biopsy.
However, as a result of the low prevalence of celiac disease among subjects on a selfinstituted GFD, estimated to be about 10% in an HLA-DQ2.5 + population in our region, 15 the estimated positive predictive value of the HLA-DQ-gluten tetramer test would be 0.67, whereas the negative predictive value would be 1.00. Due to the superior negative predictive value, we recommend a strategy to use the new test for exclusion of celiac disease. To be M A N U S C R I P T
19 compliant with current guidelines for celiac disease diagnosis, we advise that the few subjects who score positive with the HLA-DQ-gluten tetramer test should undergo gluten challenge followed by duodenal biopsy to establish the diagnosis. Hopefully, in the future the performance of the HLA-DQ-gluten tetramer test can be further improved allowing the diagnosis to made directly without the need for an oral gluten challenge.
The controls were not subjected to duodenal biopsy before inclusion, and some unrecognized cases of celiac disease could therefore be expected. Indeed, four of five controls that tested positive, were also positive for celiac disease specific serology, and two of these seropositive subjects were later diagnosed with celiac disease based on duodenal histology. A prevalence of unrecognized celiac disease of 4% (95% CI, 0-10%) in our cohort of 52 HLA-DQ2. Serology can detect dietary transgressions in celiac disease patients, 36 and may be used to assess dietary compliance in patients with lack of symptomatic remission after initiation of treatment. 37 Using CD38-expression (CD38 RR ) as a parameter for activation of the HLA-DQ-M A N U S C R I P T
gluten-tetramer + T cells, we could differentiate TCD-subjects from UCD-subjects with test accuracy similar to serology. CD38 is up-regulated on circulating gluten-specific T cells after a gluten challenge, 26 and has faster kinetics than serology (six days vs weeks to months after initiation of gluten consumption). 10, 25, 28, 38 If these fast kinetics also apply with the termination of gluten intake (currently being evaluated by us in a separate study), CD38 RR may be used as a faster response parameter in the follow-up of celiac disease. Additionally, it may be used to stratify subjects with reduced gluten intake for the GS-TCD model or control-UCD model of the HLA-DQ-gluten tetramer test.
The suggested diagnostic models should be validated in independent studies. In the case of gluten-free subjects, a validation should be carried out as a multi-center study with a retrospective confirmation of diagnosis as in the current study, or with a prospective design where at risk gluten-free subjects undergo a gluten-challenge as part of routine work-up for celiac disease. Although mimicking the clinical situation, drawbacks with the latter approach could be potential dropouts and a significant proportion of false negative histology outcome, which would complicate calculation of the accuracy of the index test. The study should be done in a blinded manner. In the current study, blinded pre-planned inclusion of UCDsubjects was not feasible, as sampling of blood for the HLA-DQ-gluten tetramer-test had to be done on the day of appointment for the routine gastroduodenoscopic examination due to subsequent initiation of a GFD.
A practical limitation, which may affect children, is the required volume of blood (54 mL). This volume may be reduced, especially if the test subject is consuming gluten. Other limitations may be the requirement to analyze the sample on the same or following day of blood draw, and the duration of time required for blood analysis. The duration of the current protocol was seven hours for five samples, including centrifugation time, incubation periods, automated HLA-DQ-gluten tetramer-enrichment and flow cytometry analysis. Parts of the process may, however, be further automated and protocol modifications for freezing down PBMC from fresh blood may allow for flexibility and increased efficiency. Finally, our study-population M A N U S C R I P T
was limited to HLA-DQ2.5 + subjects. Although, the HLA-DQ-gluten tetramer test may also be feasible in subjects with the other celiac disease associated HLA-types (HLA-DQ8 and HLA-DQ2.2), 25, 39 the diagnostic potential of the HLA-DQ-gluten tetramer test in non-HLA-DQ2.5
+ subjects remains to be tested in studies of adequate size.
In conclusion, the HLA-DQ-gluten tetramer blood test for detection of gluten-specific CD4 + T cells is a less invasive test for celiac disease and has high sensitivity and specificity, even if the subject is on a GFD. Due to the high negative predictive value in our HLA-DQ2.5 + patient population of self-instituted GFD, it can replace gluten challenge followed by duodenal biopsy for exclusion of celiac disease in a sizable majority of these patients. The new test should thus provide an attractive option for the many self-diagnosed gluten intolerant subjects, carrying the celiac disease risk gene HLA-DQ2.5 and avoiding dietary gluten. Even though the minority of subjects who are expected to test positive for the new test will be recommended to undergo a gluten challenge and duodenal biopsy to obtain the diagnosis according to current guidelines, finding motivation for the challenge should be easier knowing the high likelihood of a positive diagnostic outcome. The test should also help the clinicians to meet expectations of further risk-stratification beyond HLA-typing of this group of patients who they currently have little to offer but a general recommendation of a gluten challenge.
Efforts should be made to validate these test performances and to make the HLA-DQ-gluten tetramer test broadly available.
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Tables: Table 1 . Flow-cytometric variables.
Variable Numerator Denominator
Frequency of glutenspecific T cells Frequency of gluten-specific cells; median (25% , 75%) Significant P-values (< .05) are in bold numbers. Fisher's exact test was used in the case of ratios. Variables that were normal distributed before or after transformation were tested with two sample T-tests, and non-parametric variables were tested with Mann-Whitney test.
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Supplementary tables and supplementary figure legends:
Supplementary # Reference range; anti-TG2 IgA < 3 units, anti-DGP-IgG < 20 units/mL * The duodenal biopsy showed focal increase in IEL and focal villous changes.
** The value before the slash is the Marsh score in the second part of duodenum (descending duodenum) and the value after the slash is the Marsh score in the first part of duodenum (the duodenal bulb).
Supplementary Table 3 The reproducibility (analytical variation) and biological variation for the HLA-DQ-gluten tetramer test was examined in 10 subjects, five TCD-subjects and five controls. Blood was taken twice with one week interval to calculate the standard deviation (SD) for weekly biological variation and at each time point the sample was divided into two halves to determine the mean analytical difference and analytical SD. show the cut-off for optimal sensitivity and specificity, also shown as the horizontal dotted
